Sedana Medical

Sedana Medical
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care. Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors. Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.

Contacts

Johannes Doll

President & CEO

+46 (0)76 303 66 66
http://www.sedanamedical.com
johannes.doll@sedanamedical.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

First patient enrolled in SESAR study on lung protection

Fri, May 15, 2020 10:00 CET

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that that the first patient has been included in SESAR, the world's largest multicenter study with AnaConDa to evaluate whether inhaled sedation via AnaConDa has lung-protective properties, promotes shortened ventilator time and higher survival in intensive care patients with acute respiratory failure. An addendum to the study has recently been made to study covid-19 patients in a separate sub-study.As previously announced, Sedana Medical provides financial support to SESAR, a prospective, randomized and controlled study

Sedana Medical supports multinational study of inhaled sedation in Covid-19 ARDS

Tue, May 12, 2020 09:00 CET

Sedana Medical AB (publ) (SEDANA: FN Stockholm) meddelade idag att bolaget kommer att ge ekonomiskt stöd till en multinationell, observationsstudie där utfallet för patienter som får inhalationssedering jämförs med utfallet för patienter som får intravenös sedering.The study, Inhaled Sedation in Covid-19-related Acute Respiratory Distress Syndrome, (ISCA), is planned to enroll a minimum of 400 patients and will be conducted in approximately 30 ICUs in France, Germany, Spain and Switzerland. The primary endpoint is ventilator-free days up to day 28. “This study is highly relevant in this

Sedana Medical's sales increase around 90 percent

Mon, Apr 06, 2020 08:00 CET

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company expects sales of approximately SEK 34 million in the first quarter of 2020, corresponding to growth of around 90 percent compared to the same period last year.On March 30, Sedana Medical announced that the company is experiencing a sharp increase in demand as a result of the novel corona virus. However, sales during the last days of March turned out to be significantly higher than expected and the company now expects a significantly higher turnover for the first quarter of 2020 than announced on March 30. “

Sedana Medical sees increased demand and keeps time schedule

Mon, Mar 30, 2020 08:00 CET

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company sees increased demand for AnaConDa as a result of the Covid-19 pandemic and so far, has had no significant supply chain disruptions. Sedana Medical forecasts a sales increase of about 50 percent for the first quarter of 2020 and about 100 percent for the month of March, compared to the same periods last year. Due to the Covid-19 pandemic Sedana Medical sees a slight risk of delay of the compilation of the IsoConDa study until the beginning of the third quarter of 2020. However, this would not necessarily mean

There are no items matching the current filter

There are no more items matching the current filter

Share